Free Trial
→ Revolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial Underway (From Interactive Offers) (Ad)
NASDAQ:SCLX

Scilex 1/17/2025 Earnings Report

Scilex logo
$7.10 +0.37 (+5.42%)
As of 11:12 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Scilex EPS Results

Actual EPS
-$6.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scilex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scilex Announcement Details

Quarter
Date
1/17/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Scilex's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Scilex Earnings Headlines

SCLX Scilex Holding Company - Seeking Alpha
July 1, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/SCLX
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...
June 25, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCLX/pressreleases/33010333/scilex-holding-company-announces-deferral-of-record-date-for-its-previously-announced-dividend-of-preferred-stock-exchangeable-for-up-to-10-of-scilexs-ownership-interest-in-semnur-pharmaceuticals-inc-its-wholly-owned-subsidiary-from-may-2/
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
July 16 at 2:00 AM  |  Timothy Sykes (Ad)
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board
June 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/23/3103857/0/en/scilex-holding-company-announces-deferral-of-record-date-for-its-previously-announced-dividend-of-preferred-stock-exchangeable-for-up-to-10-of-scilex-s-ownership-interest-in-semnur.html
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal
June 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/05/3094624/0/en/scilex-holding-company-announces-publication-on-gloperba-dosing-adjustments-in-peer-review-journal.html
Scilex Holding Stock Price History
June 1, 2025  |  investing.comhttps://www.investing.com/equities/vickers-vantage-historical-data
See More Scilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email.

About Scilex

Scilex (NASDAQ:SCLX), Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of non-opioid therapies for pain management. The company’s core mission is to address unmet medical needs in patients suffering from acute and chronic pain by offering innovative topical and injectable products designed to provide targeted relief while minimizing systemic exposure.

Scilex’s lead marketed product is ZTlido, a lidocaine topical system approved for the treatment of peripheral neuropathic pain associated with post-herpetic neuralgia. In addition to ZTlido, the company’s clinical pipeline features novel formulations such as a dexamethasone gel intended for epidural administration following spinal surgery and exploratory programs targeting neuropathic pain and osteoarthritis. These products leverage proprietary drug-delivery technologies aimed at enhancing efficacy and convenience for patients.

Formed through a strategic combination of development-stage assets in the early 2020s, Scilex is headquartered in Southern California and conducts commercial and clinical activities across the United States. The company works with a network of specialty distributors, wholesalers and direct-to-physician sales channels to ensure broad access to its therapies. Scilex also collaborates with contract research organizations and manufacturing partners to support its ongoing research and development efforts.

The executive leadership team at Scilex brings together seasoned professionals with extensive backgrounds in pharmaceutical research, regulatory affairs and global commercialization. Under their guidance, the company continues to pursue strategic partnerships and licensing opportunities to expand its portfolio of non-opioid pain treatments. Looking ahead, Scilex aims to build on its existing product suite while advancing late-stage programs toward regulatory approval and market launch.

View Scilex Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles